Reset filters

Search publications


By keyword
By department

No publications found.

 

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Author(s): McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM ...

Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains com ...

Article GUID: 38596311


An Automated Single-Cell Droplet-Digital Microfluidic Platform for Monoclonal Antibody Discovery

Author(s): Ahmadi F; Tran H; Letourneau N; Little SR; Fortin A; Moraitis AN; Shih SCC;

Monoclonal antibody (mAb) discovery plays a prominent role in diagnostic and therapeutic applications. Droplet microfluidics has become a standard technology for high-throughput screening of antibody-producing cells due to high droplet single-cell confineme ...

Article GUID: 38441226


Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights

Author(s): Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ;

The Food and Drug Administration (FDA) has recently authorized the two messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 for emergency use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 coronavirus disease. ...

Article GUID: 34021862


-   Page 1 / 1   -